RECEIVED CENTRAL FAX CENTER

FEB 0 6 2004

OFFICIAL

Response to Election/Restriction

To: Renee Pettus, Biotechnology Office

ATTN: Examiner Karen A. Canella

Art Unit: 1642

Re: Application Ser. No. 09/751,708

Date of FAX: February 6, 2004

FAX no.: (703) 308-4407

No. of pages: 3

Please FAX <u>Confirmation of Receipt</u> of this FAX to: David S. Terman (831) 624-1207

PAGE 2/3 * RCVD AT 2/6/2004 5:20:25 PM [Eastern Standard Time] * SVR:USPTO-EFXRF-1/0 * DMIS:8729306 * CSID:408 624 1207 * DURATION (mm-ss):02-24

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

RECEIVED CENTRAL FAX CENTER

FEB 0 6 2004

In re: the U.S. Application)	OFF
David S.TERMAN)	
Serial No. 09/951,708)	
Filed: December 28, 2000)	
For Compositions and Methods Treatment of Neoplastic Disease	for	

PRELIMINARY AMENDMENT: RESPONSE TO ELECTION/RESTRICTION

- 1. Applicant has detected an inadventent error in electing Group claim V claims 26, 27 and 32 instead of Group claim IV claims 24, 25 and 32 in his Election/Restriction response of November 2, 2003. This was a typographical error in which the term "V" was unintentionally transcribed instead of the term "IV." It was not recognized until Applicant reviewed and responded to the second Election/Restriction from Examiner Cannela on February 6, 2004.
- 2. Applicant now respectfully requests correction of the election to Group IV claims 24, 25 and 32 for examination.
- 3. Assuming that the Examiner's request for selection of a superantigen from the list of a-f would apply to Group IV claims 24, 25 and 32, applicant responds as follows:
- 4. Applicant respectfully disagrees with the examiner that each superantigen should be placed in a separate categories. All species in a-f are clearly acknowledged as superantigens having the common properties of stimulating a large proportion of mammalian T lymphocytes selectively via the T cell $V\alpha/\beta$ regions in quantities as low as

PAGE 313 * RCVD AT 21612004 5:20:25 PM [Eastern Standard Time] * SVR:USPTO-EFXRF-110 * DNIS:8729306 * CSID:408 624 1207 * DURATION (mm-ss):02-24

10¹⁵M. They are acknowledged by those skilled in the art as a viable family and are not patentably distinct entities.

5. Applicant selects (k) gangliosides from the group listed in item 4 of the communication.

Respectfully yours,

David S. Terman, M.D.

Date: February 6, 2004